Research programme: thrombolytic therapy - Byondis
Alternative Names: BLX-155Latest Information Update: 21 Apr 2020
At a glance
- Originator Biolex
- Developer Byondis
- Class Serine endopeptidases
- Mechanism of Action Fibrinolysis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute coronary syndromes; Deep vein thrombosis; Peripheral arterial occlusive disorders
Most Recent Events
- 21 Apr 2020 Synthon Biopharmaceuticals is now called Byondis
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute coronary syndromes in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Deep-vein-thrombosis in USA (Parenteral)